Table 1.

Effect of PTX or PMA on Ang II-, PE-, and NPY-mediated PKC and MAPK activation

Agonist, M			PKC activity, %		p38 activation, %			ERK activation, %			JNK activation, %
NPY	PE	Ang II	Control	PTX	Control	PTX	PMA	Control	PTX	PMA	Control	PTX	PMA
10−7	—	—	27  ± 3*	5  ± 4	44  ± 2*	5  ± 4	5  ± 2	74  ± 2*	5  ± 4	2  ± 4	84  ± 5*	7  ± 2	4  ± 3
10−9	—	—	3  ± 2	ND	0  ± 3	−5  ± 3	ND	6  ± 5	5  ± 3	ND	41  ± 6*	3  ± 5	ND
—	10−7	—	25  ± 4*	2  ± 3	40  ± 4*	1  ± 2	2  ± 4	68  ± 3*	4  ± 5	3  ± 5	47  ± 3*	22  ± 4	2  ± 3
—	10−10	—	7  ± 3	ND	15  ± 3	2  ± 1	ND	12  ± 4	−1  ± 3	ND	10  ± 7	5  ± 3	ND
—	—	10−7	32  ± 5*	27  ± 5*	68  ± 3*	64  ± 3*	62  ± 4*	97  ± 2*	98  ± 5*	99  ± 3*	94  ± 5*	102  ± 4*	89  ± 3*
—	—	10−10	−4  ± 5	ND	11  ± 4	12  ± 3	ND	32  ± 4*	34  ± 3*	ND	21  ± 2*	19  ± 1*	ND
10−9	10−10	—	39  ± 6*	3  ± 4	81  ± 3*	7  ± 4	5  ± 3	62  ± 4*	6  ± 3	3  ± 2	91  ± 3*	7  ± 4	3  ± 1
10−9	—	10−10	5  ± 1	4  ± 3	9  ± 2	11  ± 5	ND	41  ± 4*	27  ± 5*	ND	62  ± 4*	24  ± 3*	ND

Cells were incubated with either 100 ng PTX for 6 h or 2 μM PMA for 36 h before agonist addition. Results represent percent increase as compared with untreated control ± SEM (n = 3–6). ND, not done. *, P < 0.05 compared with control.